Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells
Rachel Elizabeth Cooke, Kylie Margaret Quinn, Hang Quach, Simon Harrison, Henry Miles Prince, Rachel Koldej, David Ritchie
Frontiers in Immunology | FRONTIERS MEDIA SA | Published : 2020
New diagnoses of multiple myeloma (MM) tend to occur after the age of 60, by which time thymic output is severely reduced. As a consequence, lymphocyte recovery after lymphopenia-inducing anti-MM therapies relies on homeostatic proliferation of peripheral T cells rather than replenishment by new thymic emigrants. To assess lymphocyte recovery and phenotype in patients with newly diagnosed MM (NDMM) and relapsed/refractory MM (RRMM), we tracked CD4+ and CD8+ T cell populations at serial time points throughout treatment and compared them to age-matched healthy donors (HD). Anti-MM therapies and autologous stem cell transplant (ASCT) caused a permanent reduction in the CD4:8 ratio, a decrease i..View full abstract
This research was funded by the Leukaemia Foundation Australia and supported by the University of Melbourne, the Royal Melbourne Hospital, and the Peter MacCallum Cancer Centre. Bioinformatic analysis of the RNA-Seq data was provided by Jessica Chung at Melbourne Bioinformatics (University of Melbourne).